2024-10-13 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of life-threatening diseases.

**1. Performance Comparison:**

* **Cumulative Return:** GILD has a cumulative return of -11.95% while the S&P 500 (VOO) has a cumulative return of 135.82%. This puts GILD at a significant -147.77% underperformance compared to the benchmark.
* **Relative Divergence:** GILD's current underperformance relative to the S&P 500 falls within the 5.09th percentile of its historical range, suggesting a more pronounced underperformance than usual.

**2. Recent Price Movement:**

* **Closing Price:** $84.95
* **5-Day Moving Average:** $85.15
* **20-Day Moving Average:** $84.13
* **60-Day Moving Average:** $79.07

The recent price movement shows GILD trading slightly above its 20-day moving average, indicating some short-term bullishness. However, its price is below its 5-day moving average, suggesting a potential short-term pullback.

**3. Technical Indicators:**

* **RSI:** 55.23, indicating a neutral momentum. The RSI is above 50, but not in overbought territory.
* **PPO:** -0.21, suggesting a slight bearish momentum. The negative PPO indicates a downward trend in the stock.
* **Delta_Previous_Relative_Divergence:** -2.63, suggesting a recent short-term decline in relative performance.
* **Expected Return:** 0.0%, indicating no significant expected return relative to the S&P 500 over the next five years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for Q2 2024 (released on 2024-08-08) showed EPS of $1.29, beating the analyst consensus estimate of $1.23. The revenue of $6.95 billion was also above the estimated $6.81 billion. 

While Gilead has shown recent improvement in earnings, its long-term growth prospects remain uncertain due to patent expirations for some key drugs and competition in the market.

**5. News and Recent Issues:**

* **Recent Market Outlook for GILD:** The recent market outlook for GILD remains uncertain. While the company has shown recent earnings improvement, concerns remain regarding patent expirations for key drugs and competition in the market.
* **Analyst Opinions:** Analyst opinions on GILD are mixed. While some analysts remain optimistic about the company's future, others are more cautious.
* **Performance Highlights:** Gilead's recent performance has been impacted by the challenges mentioned above. However, the company is actively working on developing new drugs and expanding its portfolio.

**6. Overall Analysis:**

Gilead Sciences (GILD) has been underperforming the S&P 500 significantly in recent years, with a -147.77% difference in cumulative returns. While recent earnings have shown some improvement, concerns remain about patent expirations and competition. Technical indicators suggest a neutral to slightly bearish short-term outlook. The expected return is currently estimated to be 0.0%, indicating a lack of significant potential for outperformance compared to the S&P 500 over the next five years.  Overall, Gilead remains a mixed investment case, requiring careful consideration of its long-term growth prospects, competition, and ongoing product development efforts.

**7. Summary:**

Gilead Sciences, Inc. (GILD) has shown underperformance compared to the S&P 500 in recent years. While recent earnings have improved, the long-term outlook remains uncertain. The stock is trading near its 20-day moving average, suggesting some short-term bullishness, but technical indicators are mixed. Analyst opinions are mixed, and the expected return is currently low. Overall, GILD presents a mixed investment case, requiring further due diligence and consideration of its long-term growth potential and competitive landscape. 
